NANOSONICS LIMITED — Director's Dealing 2018

Mar 11, 2018

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Nanosonics Limited ABN 11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maurie Stang
Date of last notice	26 February 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	a) Direct b) Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect shares held in names of Novapharm Research (Australia) Pty Ltd and Epitek Corporation Pty Ltd
Date of change	5 March 2018
No. of securities held prior to change	a) Direct: 22,483,333 ordinary shares, fully paid. b) Indirect: 116,368 ordinary shares, fully paid.
Class	Ordinary shares, fully paid.
Number acquired	Nil
Number disposed	2,345,000 ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$6,448,750.00

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change a) Direct: 14,000,302 ordinary shares, fully paid. b) Indirect: 6,254,399 ordinary shares, fully paid (Note1). Nature of change On market sale of ordinary shares. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Note 1: 6,138,031 shares previously held directly are, since 16 October 2017, held indirectly in the name of UBS Nominees Pty Ltd.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

Director: Maurie Stang Date 12 March 2018

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002